The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition

Main Article Content

Pedro C. Barata
Moshe C. Ornstein
Jorge A. Garcia

Keywords

Advanced renal cell carcinoma, immunotherapy, mTOR inhibitors, PD-1/PD-L1, sequential therapy, VEGF inhibitors

Abstract

Despite significant changes in the therapeutic landscape of renal cell carcinoma, the majority of patients with metastatic disease eventually progress after first-line treatment with vascular endothelial growth factor receptors (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Understanding existing data on subsequent therapies is crucial to define an optimal treatment sequence following first-line failure. This review examines the data supporting currently approved agents in this setting and provides a framework for decision-making regarding treatment sequencing beyond first-line therapy with VEGFR TKIs.

Abstract 2806 | PDF Downloads 1024 HTML Downloads 1835 XML Downloads 613

References

1. McDermott DF, Regan MM, Atkins MB. Interleukin-2 therapy of metastatic renal cell carcinoma: Update of phase III trials. Clin Genitourin Cancer. 2006 Sep;5(2):114–9. http://dx.doi.org/10.3816/CGC.2006.n.027
2. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000 Feb;6(Suppl 1):S55–7.
3. Stukalin I, Alimohamed N, Heng DY. Contemporary treatment of metastatic renal cell carcinoma. Oncol Rev. 2016 Jul 01;10(1):295. http://dx.doi.org/10.4081/oncol.2016.295
4. Choueiri TK. VEGF inhibitors in metastatic renal cell carcinoma: Current therapies and future perspective. Curr Clin Pharmacol. 2011 Aug;6(3):164–8. http://dx.doi.org/10.2174/157488411797189424
5. Battelli C, Cho DC. mTOR inhibitors in renal cell carcinoma. Therapy. 2011 Jul;8(4):359–67. http://dx.doi.org/10.2217/thy.11.32
6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):115–24. http://dx.doi.org/10.1056/NEJMoa065044
7. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8. http://dx.doi.org/10.1200/JCO.2009.23.9764
8. FDA. Cabozantinib approval for the treatment of advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy [Internet]. 2016 [cited Jan 30, 2017]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm497483.html
9. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015 Nov 05;373(19):1803–13. http://dx.doi.org/10.1056/NEJMoa1510665
10. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006 Jan;12(1):122–7. http://dx.doi.org/10.1038/nm1337
11. Raimondo L, D’Amato V, Servetto A, Rosa R, Marciano R, Formisano L, et al. Everolimus induces Met inactivation by disrupting the FKBP12/Met complex. Oncotarget. 2016 Jun 28;7(26):40073–84. http://dx.doi.org/10.18632/oncotarget.9484
12. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008 Aug 09;372(9637):449–56. http://dx.doi.org/10.1016/S0140-6736(08)61039-9
13. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23(4):832–41. http://dx.doi.org/10.1200/JCO.2005.05.179
14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228–47. http://dx.doi.org/10.1016/j.ejca.2008.10.026
15. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer. 2010 Sep 15;116(18):4256–65. http://dx.doi.org/10.1002/cncr.25219
16. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet. 2011 Dec 03;378(9807):1931–9. http://dx.doi.org/10.1016/S0140-6736(11)61613-9
17. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008 Nov 15;14(22):7272–83. http://dx.doi.org/10.1158/1078-0432.CCR-08-0652
18. Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl. 2013 Sep;11(2):172–91. http://dx.doi.org/10.1016/j.ejcsup.2013.07.016
19. Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013 May;14(6):552–62. http://dx.doi.org/10.1016/S1470-2045(13)70093-7
20. Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, et al. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer. 2014 Jun 10;110(12):2821–8. http://dx.doi.org/10.1038/bjc.2014.244
21. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007 May 31;356(22):2271–81. http://dx.doi.org/10.1056/NEJMoa066838
22. Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014 Mar 10;32(8):760–7. http://dx.doi.org/10.1200/JCO.2013.50.3961
23. Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, Nordahl L, et al. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res. 2005 May 15;11(10):3633–41. http://dx.doi.org/10.1158/1078-0432.CCR-04-2129
24. Sivanand S, Pena-Llopis S, Zhao H, Kucejova B, Spence P, Pavia-Jimenez A, et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med. 2012 Jun 06;4(137):137ra75. http://dx.doi.org/10.1126/scitranslmed.3003643
25. Garcia JA, Hutson TE, Elson P, Cowey CL, Gilligan T, Nemec C, et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer. 2010 Dec 01;116(23):5383–90. http://dx.doi.org/10.1002/cncr.25327
26. Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol. 2010 Dec;58(6):906–11. http://dx.doi.org/10.1016/j.eururo.2010.09.008
27. Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: An open-label, randomised phase 3 trial. Lancet Oncol. 2014 Mar;15(3):286–96. http://dx.doi.org/10.1016/S1470-2045(14)70030-0
28. Choueiri TK, Pal SK, McDermott DF, Morrissey S, Ferguson KC, Holland J, et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol. 2014 Aug;25(8):1603–8. http://dx.doi.org/10.1093/annonc/mdu184
29. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015 Nov 05;373(19):1814–23. http://dx.doi.org/10.1056/NEJMoa1510016
30. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): Final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 Jul;17(7):917–27. http://dx.doi.org/10.1016/S1470-2045(16)30107-3
31. Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639–46. http://dx.doi.org/10.1200/JCO.2012.48.4659
32. Ornstein MC, Rini BI. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2016 Jun;16(6):577–84. http://dx.doi.org/10.1080/14737140.2016.1184980
33. Motzer RJ, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, et al., editors. CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). ASCO Annual Meeting Proceedings; 2016.
34. Cella D, Grunwald V, Nathan P, Doan J, Dastani H, Taylor F, et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: A randomised, open-label, phase 3 trial. Lancet Oncol. 2016 Jul;17(7):994–1003. http://dx.doi.org/10.1016/S1470-2045(16)30125-5
35. FDA. Nivolumab approval for the treatment of advanced renal cell carcinoma in patients who have received a certain type of prior therapy [Internet]. 2015 [cited Jan 30, 2017]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.html
36. Molina AM, Hutson TE, Larkin J, Gold AM, Wood K, Carter D, et al. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol. 2014 Jan;73(1):181–9. http://dx.doi.org/10.1007/s00280-013-2339-y
37. Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013 Oct 28;340(1):97–103. http://dx.doi.org/10.1016/j.canlet.2013.07.007
38. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008 Feb 01;122(3):664–71. http://dx.doi.org/10.1002/ijc.23131
39. Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015 Nov;16(15):1473–82. http://dx.doi.org/10.1016/S1470-2045(15)00290-9
40. Hutson TE, Dutcus CE, Ren M, Baig MA, Fishman MN. Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2016;34: (abstract 4553). http://dx.doi.org/10.1200/jco.2016.34.2_suppl.569
41. Lara PN, Redman MW. The hazards of randomized phase II trials. Ann Oncol. 2012 Jan;23(1):7–9. http://dx.doi.org/10.1093/annonc/mdr567
42. Rubinstein L, Crowley J, Ivy P, Leblanc M, Sargent D. Randomized phase II designs. Clin Cancer Res. 2009 Mar 15;15(6):1883–90. http://dx.doi.org/10.1158/1078-0432.CCR-08-2031
43. FDA. Lenvatinib in combination with everolimus [Internet]. 2016 [cited Jan 30, 2017]. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501070.html
44. Fellner C. Launch of breakthrough therapies will reshape renal cell carcinoma market. P T. 2016 Aug;41(8):523–5.
45. Herz S, Hofer T, Papapanagiotou M, Leyh JC, Meyenburg S, Schadendorf D, et al. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. Eur J Cancer. 2016 Nov;67:66–72. http://dx.doi.org/10.1016/j.ejca.2016.07.026
46. Greef B, Eisen T. Medical treatment of renal cancer: new horizons. Br J Cancer. 2016 Aug 23;115(5):505–16. http://dx.doi.org/10.1038/bjc.2016.230
47. Hammers H, Plimack ER, Infante JR, Ernstoff M, Rini BI, McDermott DF, et al. 1050ophase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (MRCC). Ann Oncol. 2014;25(suppl 4):iv361–2. http://dx.doi.org/10.1093/annonc/mdu342.3
48. Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Ernstoff M, et al., editors. Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (MRCC). ASCO Annual Meeting Proceedings; 2015.
49. Escudier BJ, Motzer RJ, Powles T, Tannir NM, Davis ID, Donskov F, et al. Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). J Clin Oncol. 2016;34:(suppl 2S; abstr 499).
50. Motzer RJ, Hutson TE, Ren M, Dutcus C, Larkin J. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol. 2016 Jan;17(1):e4–5. http://dx.doi.org/10.1016/S1470-2045(15)00543-4
51. Rini BI, Melichar B, Fishman MN, Oya M, Pithavala YK, Chen Y, et al. Axitinib dose titration: Analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. Ann Oncol. 2015 Jul;26(7):1372–7. http://dx.doi.org/10.1093/annonc/mdv103
52. Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017 Jan 26;376(4):354–66. http://dx.doi.org/10.1056/NEJMra1601333